Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ContraNPM1AML

Financiado

Cerrado

Dissecting to hit the therapeutic targets in nucleophosmin NPM1 mutated acute...

Dissecting to hit the therapeutic targets in nucleophosmin NPM1 mutated acute myeloid leukemia Acute myeloid leukemia (AML) is a group of hematologic malignancies which, due to their molecular and clinical heterogeneity, have been traditionally difficult to classify and treat. Recently, next-generation, whole-genome sequenc... ver más

31/03/2022

UNIPG

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PERUGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-03-31

ERC-2016-COG: ERC Consolidator Grant

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIPG

1.88M€ | Lider

INDUSTRIA DE TURBO PROPULSOR...

4.94M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

reMARK-AML Re-envisioning risk biomarkers in acute myeloid leukemia (AM... 150K€ Cerrado

TREAT-NPM1-AML Improving therapy of NPM1 mutated AML 3M€ Cerrado

NovLeuReg Identification and characterization of novel essential regul... 212K€ Cerrado

PID2020-117645RA-I00 IMPACTO FUNCIONAL DE LAS MUTACIONES NO CODIFICANTES ASOCIADA... 206K€ Cerrado

ALLRUN Modeling TEL AML1 childhood lymphoblastic leukemia in zebraf... 100K€ Cerrado

OncoNichPath Unmasking the dynamic influence of the hematopoietic niche a... 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2017-03-29
Fecha Fin: 2022-03-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PERUGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Acute myeloid leukemia (AML) is a group of hematologic malignancies which, due to their molecular and clinical heterogeneity, have been traditionally difficult to classify and treat. Recently, next-generation, whole-genome sequencing has uncovered several recurrent somatic mutations that better define the landscape of AML genomics. Despite these advances in deciphering AML molecular subsets, there have been no concurrent improvements in AML therapy which still relies on the ‘antracycline+cytarabine’ scheme. Hereto, only about 40-50% of adult young patients are cured whilst most of the elderly succumb to their disease. Therefore, new therapeutic approaches which would take advantage of the new discoveries are clearly needed. In the past years, we discovered and characterized nucleophosmin (NPM1) mutations as the most frequent genetic alteration (about 30%) in AML, and today NPM1-mutated AML is a new entity in the WHO classification of myeloid neoplasms. However, mechanisms of leukemogenesis and a specific therapy for this leukemia are missing. Here, I aim to unravel the complex network of molecular interactions that take place in this distinct genetic subtype, and find their vulnerabilities to identify new targets for therapy. To address this issue, I will avail of relevant pre-clinical models developed in our laboratories and propose two complementary strategies: 1) a screening-based approach, focused either on the target, by analyzing synthetic lethal interactions through CRISPR-based genome-wide interference, or on the drug, by high-throughput chemical libraries screenings; 2) a hypothesis-driven approach, based on our recent gained novel insights on the role of specific intracellular pathways/genes in NPM1-mutated AML and on pharmacological studies with ‘old’ drugs, which we have revisited in the specific AML genetic context. I expect our discoveries will lead to find novel therapeutic approaches and make clinical trials available to patients as soon as possible.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores